132 related articles for article (PubMed ID: 20943446)
1. Elevated plasma levels of urotensin II do not correlate with systemic haemodynamics in patients with cirrhosis.
Romanelli RG; Laffi G; Vizzutti F; Del Bene R; Marra F; Caini P; Guerra CT; La Villa G; Barletta G
Dig Liver Dis; 2011 Apr; 43(4):314-8. PubMed ID: 20943446
[TBL] [Abstract][Full Text] [Related]
2. Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension.
Afzelius P; Bazeghi N; Bie P; Bendtsen F; Vestbo J; Møller S
Liver Int; 2011 Oct; 31(9):1381-7. PubMed ID: 21745317
[TBL] [Abstract][Full Text] [Related]
3. [Effects of changes in central hemodynamics and hormonal systems of its regulation on the etiology of portal hypertension complications in patients with liver cirrhosis].
Tsykin DB; Iampol'skaia LI; Borisov AE; Tsykina GA; Shcherba IuV; Oktiabr'skaia IN; Levina AE
Klin Med (Mosk); 1995; 73(4):99. PubMed ID: 7474848
[No Abstract] [Full Text] [Related]
4. Cardiovascular and renal effects of low-dose atrial natriuretic peptide in compensated cirrhosis.
La Villa G; Lazzeri C; Pascale A; Sestini S; Bisi G; Sciagrà R; Vecchiarino S; Raggi VC; Barletta G; Laffi G; Gentilini P
Am J Gastroenterol; 1997 May; 92(5):852-7. PubMed ID: 9149200
[TBL] [Abstract][Full Text] [Related]
5. [Systemic hyperdynamic circulation and serum hormone concentrations in portal hypertension].
Yonekawa H; Shima S; Sugiura Y; Yoshizumi Y; Ohtsuka H; Tanaka S; Ogata T
Nihon Geka Gakkai Zasshi; 1986 Jul; 87(7):781-8. PubMed ID: 3528813
[TBL] [Abstract][Full Text] [Related]
6. Plasma substance P levels in patients with liver cirrhosis: relationship to systemic and portal hemodynamics.
Lee FY; Lin HC; Tsai YT; Chang FY; Lu RH; Hou MC; Li CP; Chu CJ; Wang SS; Lee SD
Am J Gastroenterol; 1997 Nov; 92(11):2080-4. PubMed ID: 9362197
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis.
La Villa G; Barletta G; Pantaleo P; Del Bene R; Vizzutti F; Vecchiarino S; Masini E; Perfetto F; Tarquini R; Gentilini P; Laffi G
Hepatology; 2001 Jul; 34(1):19-27. PubMed ID: 11431729
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the short-term effects of mepindolol and propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis.
Braillon A; Calès P; Lebrec D
Int J Clin Pharmacol Res; 1985; 5(4):223-8. PubMed ID: 4055165
[TBL] [Abstract][Full Text] [Related]
9. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
[TBL] [Abstract][Full Text] [Related]
10. The haemodynamic response to propranolol in cirrhosis with arterial hypertension: a comparative analysis with normotensive cirrhotic patients.
Sharma P; Kumar A; Jha S; Mishra SR; Sharma BC; Sarin SK
Aliment Pharmacol Ther; 2010 Jul; 32(1):105-12. PubMed ID: 20345511
[TBL] [Abstract][Full Text] [Related]
11. Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation.
Arkenau HT; Stichtenoth DO; Frölich JC; Manns MP; Böker KH
Z Gastroenterol; 2002 Nov; 40(11):907-13. PubMed ID: 12436367
[TBL] [Abstract][Full Text] [Related]
12. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension.
Heller J; Schepke M; Neef M; Woitas R; Rabe C; Sauerbruch T
J Hepatol; 2002 Dec; 37(6):767-72. PubMed ID: 12445417
[TBL] [Abstract][Full Text] [Related]
13. Clinical, laboratory, and hemodynamic parameters in portal hypertensive gastropathy: a study of 254 cirrhotics.
Kumar A; Mishra SR; Sharma P; Sharma BC; Sarin SK
J Clin Gastroenterol; 2010 Apr; 44(4):294-300. PubMed ID: 19730114
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis.
Genesca J; Gonzalez A; Segura R; Catalan R; Marti R; Varela E; Cadelina G; Martinez M; Lopez-Talavera JC; Esteban R; Groszmann RJ; Guardia J
Am J Gastroenterol; 1999 Jan; 94(1):169-77. PubMed ID: 9934750
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble vascular cell adhesion molecule are related to hyperdynamic circulation in patients with liver cirrhosis.
Lo Iacono O; Rincón D; Hernando A; Ripoll C; Catalina MV; Salcedo M; Clemente G; Gomez J; Nuñez O; Matilla A; Bañares R
Liver Int; 2008 Sep; 28(8):1129-35. PubMed ID: 18482273
[TBL] [Abstract][Full Text] [Related]
16. Haemodynamic derangement in human immunodeficiency virus-infected patients with hepatitis C virus-related cirrhosis: the role of bacterial translocation.
Montes-de-Oca M; Blanco MJ; Marquez M; Soto MJ; Fernandez-Gutiérrez C; Rodriguez-Ramos C; Giron-Gonzalez JA
Liver Int; 2011 Jul; 31(6):850-8. PubMed ID: 21645216
[TBL] [Abstract][Full Text] [Related]
17. Splanchnic and systemic haemodynamic response to volume changes in patients with cirrhosis and portal hypertension.
Vlavianos P; Mac Mathuna P; Williams R; Westaby D
Clin Sci (Lond); 1999 May; 96(5):475-81. PubMed ID: 10209079
[TBL] [Abstract][Full Text] [Related]
18. The effect of valsartan, an angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in liver cirrhosis.
Fierbinteanu-Braticevici C; Dragomir P; Tribus L; Negreanu L; Bengus A; Usvat R; Andronescu D
J Gastrointestin Liver Dis; 2006 Dec; 15(4):337-42. PubMed ID: 17205144
[TBL] [Abstract][Full Text] [Related]
19. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension.
Kemp W; Krum H; Colman J; Bailey M; Yandle T; Richards M; Roberts S
Liver Int; 2007 Nov; 27(9):1232-9. PubMed ID: 17919235
[TBL] [Abstract][Full Text] [Related]
20. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis.
Fernández-Rodriguez CM; Romero J; Petros TJ; Bradshaw H; Gasalla JM; Gutiérrez ML; Lledó JL; Santander C; Fernández TP; Tomás E; Cacho G; Walker JM
Liver Int; 2004 Oct; 24(5):477-83. PubMed ID: 15482346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
